Boone Capital Management LLC Buys New Shares in Tyra Biosciences, Inc. $TYRA

Posted by Stanley Muller on Jun 18th, 2026

Boone Capital Management LLC bought a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 398,482 shares of the company’s stock, valued at approximately $10,476,000. Tyra Biosciences comprises 3.5% of Boone Capital Management LLC’s investment portfolio, making the stock its 13th largest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its stake in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. AQR Capital Management LLC lifted its stake in Tyra Biosciences by 2.0% during the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock valued at $753,000 after purchasing an additional 562 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Tyra Biosciences by 5.0% during the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock valued at $404,000 after acquiring an additional 725 shares during the period. Deutsche Bank AG raised its holdings in shares of Tyra Biosciences by 5.8% during the fourth quarter. Deutsche Bank AG now owns 16,377 shares of the company’s stock valued at $431,000 after acquiring an additional 894 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Tyra Biosciences by 12.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,432 shares of the company’s stock valued at $380,000 after acquiring an additional 1,631 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Bank of America boosted their price target on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Piper Sandler boosted their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a report on Friday, March 20th. Cantor Fitzgerald initiated coverage on shares of Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Get Our Latest Analysis on Tyra Biosciences

Tyra Biosciences Stock Performance

Tyra Biosciences stock opened at $29.07 on Thursday. The firm has a market cap of $1.73 billion, a PE ratio of -13.33 and a beta of 0.75. The firm’s 50 day moving average price is $33.04 and its two-hundred day moving average price is $31.20. Tyra Biosciences, Inc. has a twelve month low of $8.98 and a twelve month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Equities analysts anticipate that Tyra Biosciences, Inc. will post -2.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director owned 28,231 shares in the company, valued at approximately $1,043,700.07. This represents a 33.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 12.50% of the company’s stock.

About Tyra Biosciences

(Free Report)

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.